Press Releases

Company press releases and official corporate announcements.

A centralized feed of corporate press releases, earnings announcements, mergers, and official statements. Content is presented for informational purposes and may require additional analysis for market relevance.

Articles

24,446 total articles

Enovis™ Companion Animal Health Launches CT-RevitL™, the Next-Generation Laser Therapy System for Veterinary Care

Enovis™ Companion Animal Health Launches CT-RevitL™, the Next-Generation Laser Therapy System for Veterinary Care

Enovis Corporation's Companion Animal Health division has launched CT-RevitL™, a next-generation photobiomodulation (PBM) laser therapy system in the U.S. Designed to deliver deeper, faster, and more consistent therapeutic outcomes, CT-RevitL integrates COMPASS technology for precise and calibrated dosing. This innovation supports veterinary practi…

Cue Biopharma Appoints Dominic Borie, M.D., Ph.D., as Chief Medical Officer and Head of Research & Development

Cue Biopharma Appoints Dominic Borie, M.D., Ph.D., as Chief Medical Officer and Head of Research & Development

Cue Biopharma announced the appointment of Dominic Borie, M.D., Ph.D., as Chief Medical Officer and Head of Research & Development. Dr. Borie brings over two decades of experience in immunology and clinical development, previously serving in leadership roles at major biotech and pharmaceutical companies. This strategic hire aligns with Cue Biopharm…

Aterian Issues Urgent Call to Action: Only 285,000 Votes or 2.7% Separates Stockholders From Securing Value

Aterian Issues Urgent Call to Action: Only 285,000 Votes or 2.7% Separates Stockholders From Securing Value

Aterian, Inc. has postponed its special shareholder meeting to July 17, 2026, urging shareholders to approve the proposed asset sale of its marquee brand portfolios and an accompanying investment transaction. The company warns that failure to approve these proposals could result in common stockholders receiving very little to no value. The asset sa…

Guardforce AI to Present Live, Answer Questions, at Skyline Signature Series™ on July 22, 2026, at 11:00 AM ET

Guardforce AI to Present Live, Answer Questions, at Skyline Signature Series™ on July 22, 2026, at 11:00 AM ET

Guardforce AI Co., Limited announced that its management team including CEO Lei Wang will present at the Skyline Signature Series on July 22, 2026, to discuss recent strategic innovations such as their AI for Service Operating System. The live, interactive event aims to connect with investors and provide insights into the company's advancements in …

Mingteng International Announces Full Launch of ERP and MES Systems, Advancing Digitalization in Mold Manufacturing

Mingteng International Announces Full Launch of ERP and MES Systems, Advancing Digitalization in Mold Manufacturing

Mingteng International Corporation Inc., a Nasdaq-listed automotive mold developer in China, announced the complete rollout of its Enterprise Resource Planning (ERP) and Manufacturing Execution System (MES) at its Wuxi subsidiary. This digital transformation shift aims to improve operational efficiency, cost management, and delivery precision, supp…

Braiin Launches Agentic AI Workforce ARIA to Capture the US$32.0 Billion Global Real Estate Software Market by 2033

Braiin Launches Agentic AI Workforce ARIA to Capture the US$32.0 Billion Global Real Estate Software Market by 2033

Braiin Limited announced the release of ARIA, an agentic AI-native workforce platform designed to automate and streamline multi-step workflows across property management, leasing, compliance, accounting support, and customer engagement in the real estate sector. ARIA aims to reduce manual administrative tasks and improve operational efficiency by c…

Pliant Therapeutics Names Flavia Borellini, Ph.D. and Robert Iannone, M.D., M.S.C.E. to Board of Directors

Pliant Therapeutics Names Flavia Borellini, Ph.D. and Robert Iannone, M.D., M.S.C.E. to Board of Directors

Pliant Therapeutics announced the appointments of Dr. Flavia Borellini and Dr. Robert Iannone to its Board of Directors, bringing extensive global oncology drug development and regulatory expertise. These additions aim to support the advancement of Pliant's clinical-stage integrin-based drug programs, including its lead candidate PLN-101095 targeti…

Syntec Optics (Nasdaq: OPTX) Adds Two New Artificial Intelligence AR Defense Tech Products to its Lineup

Syntec Optics (Nasdaq: OPTX) Adds Two New Artificial Intelligence AR Defense Tech Products to its Lineup

Syntec Optics Holdings announced new orders for two advanced ballistic-grade display windows designed for soldier Augmented Reality systems incorporating Artificial Intelligence. These new products enhance high-fidelity eye-tracking and specialized illumination capabilities, marking a significant expansion in Syntec's role in U.S. military AR moder…

Safe Pro Awarded U.S. Air Force SBIR Contract for AI Dataset Development for Use in Airfield Operations

Safe Pro Awarded U.S. Air Force SBIR Contract for AI Dataset Development for Use in Airfield Operations

Safe Pro Group Inc., a Nasdaq-listed company specializing in AI-enabled defense and security solutions, has been awarded a Small Business Innovation Research (SBIR) contract by AFWERX, the innovation arm of the U.S. Air Force. The contract focuses on developing an AI dataset using images of Foreign Object Debris/Damage encountered in Air Force and …

Voyager Demonstrates Single IV Dose of VY1706 Well Tolerated, Reduced Tau in 6-Month GLP Toxicology Study; Initiation of Clinical Trial in Alzheimer’s Disease Expected H2 2026

Voyager Demonstrates Single IV Dose of VY1706 Well Tolerated, Reduced Tau in 6-Month GLP Toxicology Study; Initiation of Clinical Trial in Alzheimer’s Disease Expected H2 2026

Voyager Therapeutics announced positive six-month GLP toxicology study results for VY1706, their investigational gene therapy targeting tau protein in Alzheimer's disease. The therapy showed good tolerability and up to 75% sustained tau reduction in key brain regions of non-human primates following a single intravenous dose. With FDA IND clearance …

Malibu Boats Refinances Credit Facility on the Strength of Its Balance Sheet, Extending Maturity to 2031

Malibu Boats Refinances Credit Facility on the Strength of Its Balance Sheet, Extending Maturity to 2031

Malibu Boats, Inc. has successfully refinanced its credit facility, replacing the prior agreement with Truist Bank. The new financing structure introduces a $100 million term loan alongside a $250 million revolving credit facility, extending the maturity date from 2027 to 2031. This strategic move enhances the company's financial flexibility to inv…

Immutep Provides Clinical Update in 1st line NSCLC: Positive Mature Overall Survival Data from INSIGHT-003 and Update from TACTI-004

Immutep Provides Clinical Update in 1st line NSCLC: Positive Mature Overall Survival Data from INSIGHT-003 and Update from TACTI-004

Immutep Limited reported mature overall survival data from its INSIGHT-003 Phase I trial involving eftilagimod alfa combined with pembrolizumab and chemotherapy in first-line non-squamous NSCLC patients. The median overall survival reached 30.9 months, outperforming historical benchmarks, particularly benefiting patients with low PD-L1 expression. …

Sana Biotechnology Announces Follow-On Publication in The New England Journal of Medicine (NEJM) Highlighting Groundbreaking Long-Term Data and Durability of Hypoimmune-Modified Islet Cell Transplantation Without Immunosuppression in Type 1 Diabetes

Sana Biotechnology Announces Follow-On Publication in The New England Journal of Medicine (NEJM) Highlighting Groundbreaking Long-Term Data and Durability of Hypoimmune-Modified Islet Cell Transplantation Without Immunosuppression in Type 1 Diabetes

Sana Biotechnology announced publication in The New England Journal of Medicine of a peer-reviewed letter detailing 14-month follow-up data from a study of its hypoimmune (HIP)-modified pancreatic islet cell therapy. The data demonstrate safety, immune evasion, and durable insulin production without immunosuppression in type 1 diabetes patients. Sa…

Enlivex Receives FDA Regenerative Medicine Advanced Therapy (RMAT) Designation for Allocetra™ in Age-Related Knee Osteoarthritis

Enlivex Receives FDA Regenerative Medicine Advanced Therapy (RMAT) Designation for Allocetra™ in Age-Related Knee Osteoarthritis

Enlivex Ltd. announced that the FDA granted Regenerative Medicine Advanced Therapy (RMAT) designation to Allocetra™, its clinical-stage immunotherapy for treating age-related primary knee osteoarthritis in patients aged 64 and older. This designation enables early FDA engagement, potential accelerated approval, and priority review, supporting faste…

Tactile Medical Enters Exclusive U.S. Distribution Agreement with ElastiMed for its MyoSleeve™ Wearable Compression Device for VA and DoD Patients

Tactile Medical Enters Exclusive U.S. Distribution Agreement with ElastiMed for its MyoSleeve™ Wearable Compression Device for VA and DoD Patients

Tactile Systems Technology has entered into an exclusive agreement to distribute ElastiMed's MyoSleeve, a wearable compression device for chronic swelling, across U.S. Department of Veterans Affairs and Department of Defense patients. The MyoSleeve offers a discreet, cable-free therapy option suitable for earlier stages of chronic swelling, complem…